Table A2. Detailed data for spasticity limiting function in community follow-up.
| Category | Characteristic | Level | OR (95% CI) | Variable Importance Probability |
|---|---|---|---|---|
| Admission | ||||
| Demographics | Gender | Female | 1 | – |
| Male | 1.06 (0.96, 1.18) | 0.558 | ||
| Age (10 years) | 0.96 (0.93, 0.98) | 0.98 | ||
| Living arrangement | Alone | 1 | – | |
| Not alone | 0.94 (0.85, 1.05) | 0.549 | ||
| Household income | ≥ 20K | 1 | – | |
| < 20K | 0.98 (0.85, 1.14) | 0.589 | ||
| Education | No Diploma or G.E.D | 1 | – | |
| Diploma | 0.90 (0.80, 1.01) | 0.633 | ||
| Trauma | GCS facility | Mild | 1 | – |
| Moderate | 1.12 (0.78, 1.61) | 0.741 | ||
| Severe | 1.04 (0.87, 1.25) | 0.525 | ||
| GCS field | Mild | 1 | – | |
| Moderate | 1.38 (1.05, 1.81) | 0.888 | ||
| Severe | 1.06 (0.88, 1.28) | 0.536 | ||
| Medical history | Comorbidities | None | 1 | – |
| At least one | 0.98 (0.88, 1.10) | 0.553 | ||
| Missing | 1.03 (0.79, 1.34) | 0.052 | ||
| Cannabis use at Admission | No | 1 | - | |
| Yes | 1.00 (0.88, 1.15) | 0.6 | ||
| Discharge | ||||
| Neurology | AIS | A | 1 | – |
| B | 0.93 (0.80, 1.08) | 0.622 | ||
| C | 1.29 (1.06, 1.56) | 0.977 | ||
| D | 1.01 (0.77, 1.32) | 0.499 | ||
| E | 0.93 (0.59, 1.48) | 0.256 | ||
| AIS motor score (20 points) | 0.94 (0.73, 1.22) | 0.428 | ||
| Increase in AIS motor score (20 points) | 1.04 (0.98, 1.10) | 0.849 | ||
| AIS UEMS (20 points) | 1.08 (0.83, 1.40) | 0.461 | ||
| AIS LEMS (20 points) | 1.12 (0.81, 1.53) | 0.434 | ||
| Neurological level | C1–C8 | 1 | – | |
| T1–T12 | 1.07 (0.83, 1.38) | 0.402 | ||
| L1–S5 | 1.19 (0.88, 1.61) | 0.475 | ||
| C1–T12 + L1–S5 | 0.66 (0.44, 0.98) | 0.756 | ||
| Motor neuro level | C1–C8 | 1 | – | |
| T1–T12 | 0.93 (0.74, 1.17) | 0.369 | ||
| L1–S5 | 0.74 (0.54, 1.02) | 0.887 | ||
| C1–T12 + L1–S5 | 0.44 (0.31, 0.63) | 0.516 | ||
| Course of care | Operation | No | 1 | – |
| Yes | 1.03 (0.89, 1.20) | 0.698 | ||
| Gabapentin, within 1 month | No | 1 | – | |
| Yes | 0.94 (0.85, 1.04) | 0.55 | ||
| Length, inpatient stay (30 days) | 0.95 (0.91, 0.99) | 0.727 | ||
| Rehab | No | 1 | – | |
| Yes | 1.21 (1.05, 1.40) | 0.818 | ||
| Length, rehab (30 days) | 1.03 (0.98, 1.08) | 0.191 | ||
| Pain | Pain, activity | None | 1 | – |
| Mild | 1.02 (0.87, 1.18) | 0.367 | ||
| Moderate | 1.10 (0.93, 1.30) | 0.937 | ||
| Severe | 0.89 (0.71, 1.13) | 0.525 | ||
| Pain, QOL | None | 1 | – | |
| Mild | 1.06 (0.91, 1.24) | 0.465 | ||
| Moderate | 1.05 (0.88, 1.25) | 0.445 | ||
| Severe | 1.20 (0.99, 1.47) | 0.852 | ||
| Pain, sleep | None | 1 | – | |
| Mild | 0.95 (0.84, 1.08) | 0.467 | ||
| Moderate | 0.91 (0.78, 1.06) | 0.703 | ||
| Severe | 1.16 (0.98, 1.38) | 0.883 | ||
| Spasticity | PSFS | 0 | 1 | – |
| 1 | 1.20 (1.07, 1.35) | 0.825 | ||
| 2 | 1.49 (1.28, 1.75) | 0.998 | ||
| 3 | 1.37 (1.15, 1.63) | 0.944 | ||
| 4 | 1.67 (1.28, 2.19) | 0.977 | ||
| Discharge anti-spasticity medication | No | 1 | – | |
| Yes | 1.18 (1.04, 1.33) | 0.998 | ||